drugset / Trial / NCT00344760
A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
We hypothesize that using a potent antiretroviral such as Enfuvirtide during the induction phase of HAART therapy will lead to faster clearance of virus and infected cells, and lower number of minority variant HIV-1 strains.
Timeline
- Start
- 2005-01
- Primary completion
- 2007-03
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enfuvirtide | Peptide | 90 mg | Subcutaneous |
| Background | Efavirenz | Other / unclassified | 600 mg | — |
| Background | Lamivudine | Other / unclassified | 300 mg | — |
| Background | Tenofovir | Small molecule | 300 mg | — |